## **CLAIMS**


Sw.

15

1. A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] hiazolidine-2,4-dione, maleic acid salt (the Polymorph) characterised in that it provides:

- (i) an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm<sup>-1</sup>; and/or
- (ii) a Raman spectrum containing peaks at 1762, 1284, 912 and 888 cm<sup>-1</sup>; and/or
- (iii) a solid-state <sup>13</sup>C nuclear magnetic resonance spectrum containing peaks at 111.0, 113.6, 119.8, 129.1, 130 9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5,
- 171.0, 178.7 ppm; and/or
  (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms
  - 2.. A Polymorph according to claim 1, which provides an infra red spectrum substantially in accordance with kigure I.
    - 3. A Polymorph according to claim 1 or claim 2, which provides provides a Raman spectrum substantially in accordance with Figure II.
    - 4. A Polymorph according to any one of claims 1 to 3, which provides provides a solid-state <sup>13</sup>C nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.
- 5. A Polymorph according to any one of claims 1 to 3, which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II.
  - 6. A Polymorph according to any one of claims 1 to 5, in isolated form.
- 30 7. A Polymorph according to any one of claims 1 to 6, in pure form.
  - 8. A Polymorph according to any one of claims 1 to 7, in crystalline form.
- 9. A process for preparing a Polymorph according to claim 1, characterised in that either:
  - (a) Compound (I) is suspended in acetone and stirred at an elevated temperature for an extended period of time; or





after which time the Polymorph is recovered from the denatured ethanol.

5

- 10. A pharmaceutical composition comprising an effective, non-toxic amount of a Polymorph according to claim 1 and a pharmaceutically acceptable carrier therefor.
- 11. A Polymorph according to claim 1, for use as an active therapeutic substance.

10

12. A Polymorph according to claim 1, for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

15

13. The use of Polymorph for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

504 93 14. A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph to a human or non-human mammal in need thereof.

